smaller incision, new generation implantable miniature telescope (SING-IMT) for Geographic Atrophy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Atlantic Eye Surgery Center, Eatontown, NJ
Geographic Atrophy+2 More
smaller incision, new generation implantable miniature telescope (SING-IMT) - Device
Eligibility
65+
All Sexes
What conditions do you have?
Select

Study Summary

The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).

Eligible Conditions

  • Geographic Atrophy
  • Age - Related Macular Degeneration (AMD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Geographic Atrophy

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: Approximately 12-months post-operatively (330-420 days)

Day 420
Adverse Events
Anterior Chamber Depth
Best-corrected distance visual acuity (BCDVA)
Best-corrected near visual acuity (BCNVA)
IMT position
Posterior Capsule Opacification
Primary Effectiveness Outcome
Primary Safety Outcome

Trial Safety

Safety Progress

1 of 3

Other trials for Geographic Atrophy

Trial Design

1 Treatment Group

SING-IMT Implanted
1 of 1
Experimental Treatment

125 Total Participants · 1 Treatment Group

Primary Treatment: smaller incision, new generation implantable miniature telescope (SING-IMT) · No Placebo Group · N/A

SING-IMT Implanted
Device
Experimental Group · 1 Intervention: smaller incision, new generation implantable miniature telescope (SING-IMT) · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 12-months post-operatively (330-420 days)
Closest Location: Atlantic Eye Surgery Center · Eatontown, NJ
N/AFirst Recorded Clinical Trial
1 TrialsResearching Geographic Atrophy
0 CompletedClinical Trials

Eligibility Criteria

Age 65+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 65 years of age.\n
You have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by standard of care fluorescein angiography (FA) prior to the Pre-operative Visit.
You do not need treatment for CNV over the past 6 months.
You have no active exudative fluid on OCT over the past 6 months.
You have no retinal hemorrhage over a 6-month period or longer.
Have evidence of visually significant cataract at the Pre-operative Visit.
You have adequate peripheral vision at the Pre-operative Visit to allow navigation.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.